Autoantibodies to the Insulin Receptor

EFFECT ON THE INSULIN-RECEPTOR INTERACTION IN IM-9 LYMPHOCYTES

JEFFREY S. Flier, C. RONALD KAHN, DAVID B. JARRETT, and JESSE ROTH,
Diabetes Branch, National Institute of Arthritis, Metabolism, and Digestive
Diseases, National Institutes of Health, Bethesda, Maryland 20014

ABSTRACT The serum of some patients with insulin-resistant “diabetes” contains antibodies that
bind to and block the cell membrane receptors for insulin. In this report, we have characterized the ef-
fec ts of the antireceptor antibodies on the interaction of 125I-insulin with its receptor on the human
lymphoblastoid cell line IM-9. Up to 95% of specific insulin binding can be inhibited by pretreatment
of the cells with these immunoglobulins. The onset of the inhibitory effect is time- and temperature-de-
dependent, and the effect is reversed extremely slowly if the cells are suspended in a large excess of anti-
body-free buffer. These features of antibody binding can be easily distinguished from those for insulin
binding to its receptor. The inhibitory effect of the antibodies can be reversed by exposure of the cells
to conditions known to elute surface immunoglobulins.

The three antireceptor sera studied appear to alter the insulin-receptor interaction in different ways.
Two antisera markedly reduce receptor affinity through combined effects on the insulin association and dis-
sociation rates, and, additionally, have smaller effects on available receptor number. A third antisemr
primarily affects available receptor number and has little effect on receptor affinity. All three antisera
inhibit the capacity of insulin to promote negatively cooperative site-site interactions among insulin
receptors. The data suggest that these autoantibodies to the insulin receptor bind to different determinants
on the receptor and may therefore be useful as

unique probes of insulin receptor structure and func-
tion.

INTRODUCTION

We have recently described two clinical syndromes characterized by severe insulin resistance, acanthosis
nigricans, and a marked defect at the level of the membrane receptor for insulin (1). These two syn-
dromes, referred to as types A and B, can be distinguished on clinical grounds, and by the fact that
type B patients have a circulating inhibitor of insulin receptor binding (2). In a previous report, we have
shown that the circulating inhibitors in these patients are polyclonal immunoglobulins, primarily of the
IgG class, and that their inhibitory activity is mediated through the F(ab')2 portion of the molecule (3).
Further, several lines of evidence strongly suggest that these antibodies act by binding directly to
determinants on, or intimately linked to, the insulin receptor molecule (2-4). Thus, these immunoglobulins
may be considered to be “antireceptor antibodies” such as those which have been proposed as
etiologic factors in Graves’ disease (5) and myasthenia gravis (6).

Our initial description and characterization of these antibodies was based on a simple assay in which
normal cells or membranes were exposed to serum or immunoglobulin fractions for 1 h at 4°C or 22°C,
thoroughly washed, and then exposed to 125I-insulin for binding assay (2, 3). In this report, we explore in
more detail the effects of these antireceptor antibo dies on 125I-insulin binding to its receptors on the
human lymphoblastoid cell of the IM-9 line. We report data on (a) the kinetics of onset and reversal of
antibody action, (b) the variable effects of these antibodies on the kinetics of insulin association,
dissociation, and insulin-induced negative cooperativ-
ity, and (c) the effects of these antibodies on the affinity and number of residual insulin receptors. Taken together, these data indicate that antibodies to the insulin receptor impair insulin binding by a variety of mechanisms, and that sera from different patients may differ in the precise locus of their actions.

**Methods**

Human lymphoblastoid cells (IM-9), maintained in continuous culture in plastic flasks, were grown to stationary phase at 37°C in Eagle’s Minimum Essential Medium (National Institutes of Health Media Unit) supplemented with 10% fetal calf serum, penicillin, and streptomycin. Glutamine (0.26 mg/ml) was added to the medium just before transfer of the cells on the day of feeding. Cells were split twice a week and fresh media was added. Viability of cells was monitored by trypan blue dye exclusion and was always >90%. Previous studies (7) have shown that insulin receptors on these cells have binding properties essentially identical to those of insulin receptors on more classic targets of insulin action such as liver (8) and fat (9). Porcine insulin (Eli Lilly Co., Indianapolis, Ind.) was iodinated to a sp act of 100–200 μCi/μg by a modification of the chloramine-T method (10).

All sera were obtained after an overnight fast and were stored at −20°C until use. The notation for identification of sera corresponds to that employed in a previous publication (1).

**Preincubation with serum.** IM-9 cells were sedimented and resuspended at a concentration of 15 × 10^6/ml in an assay buffer containing 100 mM Heps, 120 mM NaCl, 1.2 mM MgSO4, 2.5 mM KCl, 10 mM glucose, 1 mM EDTA, and 1% bovine serum albumin, pH 7.6. Patient or control sera were diluted with phosphate-buffered saline (PBS), pH 7.6, and then incubated for various periods at the indicated temperatures with an equal volume of the cell suspension to give the final serum dilution as indicated in the legend to the figures. After preincubation, cells were washed three times with 3 vol of PBS and resuspended in assay buffer at a concentration of 15 × 10^6 cells/ml for insulin binding study. Previous studies have shown (2) that exposure of cells to normal serum to which high concentrations of insulin (50 ng/ml) have been added causes no reduction of subsequent 125I-insulin binding under these conditions of preincubation and extensive washing.

**Insulin binding studies.** After preincubation of cells as described, the binding of 125I-insulin to these cells was determined in a variety of ways: (a) the effects of duration and temperature of serum preincubation on binding inhibition; (b) the time-course and temperature dependence of recovery of binding in the absence of serum; (c) the reversal of binding inhibition by acid wash; (d) the effect of serum treatment on association rate of 125I-insulin; (e) the effect of serum treatment on dissociation rate of 125I-insulin in the presence and absence of unlabeled insulin; (f) the effect of serum treatment on steady-state insulin binding. The details of these procedures are contained within the legends to the figures.

**Data analysis.** The data on steady-state binding of 125I-insulin to its receptor is presented in three ways, each of which emphasizes different quantitative aspects of the binding interaction. (a) The percent of total radioactivity

---

1. Abbreviations used in this paper: B/F, bound/free; PBS, phosphate-buffered saline; R0, receptor concentration.

**Results**

**Effect of preincubation with undiluted sera on subsequent insulin binding.** Undiluted sera from six patients with extreme insulin resistance (types A and B) were assayed for ability to inhibit insulin binding to IM-9 lymphocytes after preincubations of increasing durations at 37°C (Fig. 1). The two sera (B-2 and B-3) from the type B patients who displayed the greatest clinical insulin resistance produced nearly maximal inhibition after 5 min of preincubation. With these sera, 96 and 90% of specific binding were prevented, respectively. Serum B-1, obtained from a patient with less severe insulin resistance, produced a time-dependent increase in inhibition, with maximal effect not yet obtained after 3 h.

Sera A-1, A-2, and A-3, obtained from patients with insulin resistance and a severe insulin receptor deficiency with an apparently distinct etiologic basis (1), caused no significant inhibition of binding after 3 h of preincubation at 37°C. It is notable that serum insulin concentrations in these type A patients were comparable to those of type B patients, thus providing an internal control against a possible role for insulin in the production of the observed inhibitory effect.

**Effect of duration and temperature of preincubation on subsequent insulin binding.** To enable a comparison of the temperature dependence and time-
course of onset of inhibitory effect in these three sera, cells were preincubated with dilutions of sera designed to produce comparable reductions of binding (about 50% of control; Fig. 2). These dilutions were 1:4, 1:4,000, and 1:80 for sera B-1, B-2, and B-3, respectively. Under these conditions, sera B-2 and B-3 showed rates of onset of inhibition that were greater at 37°C than at 22°C, which in turn were greater than that at 4°C. With serum B-1, there was a different temperature dependence, with 22° > 37° > 4°C. Because maximum inhibition had not been reached at every temperature by 180 min, it is uncertain whether temperature affected only rate of onset of inhibition (and presumably antibody binding) or maximal extent of inhibition as well. It should be noted that sera A-1, A-2, and A-3, which produced no binding inhibition at 37°C (Fig. 1), also had no effect at 4° or 22°C (data not shown).

Reversal of inhibitory effects. When compared to the time-course of onset of antibody inhibition of insulin binding, cells treated with serum B-2 were slow to recover insulin binding when washed and re-
Antireceptor antibodies are eluted from the cells by acid wash, and that these eluted antibodies are enriched for specific binding to the insulin receptor.

Effect of preincubation with serum on [125I]-insulin binding at steady state. To examine the nature of the binding inhibition produced by antireceptor antibodies, cells were preincubated with sera or buffer and washed as indicated, following which steady state insulin binding was measured over a wide range of insulin concentrations. When B/F of the labeled hormone is plotted as a function of total hormone concentration (Fig. 5), the curves for the serum-treated cells show a reduced B/F compared to buffer-treated cells over the entire range of insulin concentrations, from 0.2 to 100 ng/ml. When the B/F for the labeled hormones is expressed as a function of total hormone bound (B), i.e. Scatchard plot, curvilinear

suspended in a large excess of buffer (Fig. 3). Very similar results were obtained with sera B-1 and B-3 (data not shown). When cells were diluted in buffer at 4°C or 22°C, no recovery of insulin binding was detectable at 3 h, and at 37°C binding increased by only 10% after 3 h. The very slow rate of recovery of insulin binding after antibody treatment should be compared to the much more rapid recovery of insulin binding when insulin itself is dissociated from its receptor on these or other cells (7).

To further explore the reversible nature of antibody-mediated binding inhibition, we exposed normal cells and cells which had been antibody-treated to wash conditions known to elute antibodies from cell membranes (14; Fig. 4). Cells in which insulin binding had been reduced by preincubation with antibody showed a threefold increase of insulin binding after acid wash, suggesting that the inhibition of binding caused by the antibody can be reversed after the antibody is eluted. The level of binding did not return entirely to normal, however, probably as a result of damage to the receptor caused by the acid conditions of the wash. Brief exposure of normal cells to the same wash conditions resulted in a reduction in binding to the same level as observed in the antibody-treated cells which had been acid washed. In a previous study, with [125I]-labeled antibodies from this serum (4), we have demonstrated directly that the

![Figure 3](image_url) Reversal of antireceptor antibody effect by dilution. 30 × 10^6 IM-9 lymphocytes in 1.5 ml of assay buffer were incubated at 22°C for 60 min with either 1.5 ml of a 1:2,000 dilution of serum B-2 (to give a final dilution of 1:4,000) or with an equal volume of assay buffer alone. After preincubation, cells were washed three times with 6 ml of PBS at 22°C, and then resuspended in 3 ml of assay buffer at 4°C. Duplicate 100-µl samples of the resuspended cell suspensions were added to tubes containing 5.0 ml of assay buffer at 37°, 22°, or 4°C. After 1, 2, or 3 h, cells were sedimented, and the pellet was resuspended in 0.5 ml of assay buffer for [125I]-insulin binding assay as described in the legend to Fig. 1. Results, expressed as percent of control binding at each time-point, were calculated by dividing the percent bound to serum-treated cells, by the percent bound to identically handled buffer-treated cells and multiplying by 100.

![Figure 4](image_url) Reversal of antireceptor antibody effect by acid wash. 3 × 10^6 IM-9 lymphocytes in 0.2 ml of assay buffer were incubated at 22°C for 60 min with 0.2 ml of serum B-2 diluted 1:100 in assay buffer or with buffer alone. After preincubation, cells were washed three times in 1 ml of PBS pH 7.6 at 22°C. After the third wash, cell pellets were resuspended in 1.0-ml vol of either a glycine HCl buffer, pH 3.0, that contained 3 mg/ml bovine serum albumin (14) or assay buffer, pH 7.6, for 1 or 10 min, as indicated. Cells were then sedimented, washed twice in 2 ml of assay buffer, and finally resuspended in 0.5 ml of assay buffer for insulin binding assay as described in the legend to Fig. 1. Results are expressed as the percent of [125I]-insulin bound in each case.

*Effect of Antireceptor Antibodies on the Insulin Receptor* 787
FIGURE 5 Effect of antireceptor antibody on insulin binding at steady state. $3 \times 10^6$ IM-9 lymphocytes in 0.2 ml of assay buffer were incubated at 22°C for 60 min with 0.2 ml of dilutions of each sera, to give the final dilutions as indicated. Cells were then washed as described in the legend to Fig. 1, and the pellets were resuspended in tubes containing 0.5 ml of assay buffer, 100 pg of $^{125}$I-insulin, and different amounts of unlabeled insulin, as seen on the horizontal axis. After incubation at 15°C for 90 min, duplicate 200-μl samples were removed, and the $^{125}$I-insulin bound to the pellet was determined as described in the legend to Fig. 1. B/F of the labeled hormone is plotted as a function of the total insulin in each tube.

plots are obtained (Fig. 6). As shown by De Meyts et al. (12), these curvilinear plots are consistent with insulin binding sites that exhibit receptor site-site interactions of the negative cooperative type. As discussed in Methods, the total binding capacity or receptor concentration ($R_b$) can be calculated from the intercept of the curve with the horizontal axis. As seen in Fig. 6 and Table I, serum treatment does, in each case, result in some reduction in the calculated $R_b$. If the action of these antibodies was solely to decrease the number of functional receptors, without altering receptor affinity or site-site interactions, we would expect a parallel leftward shift of the Scatchard curve. This was indeed the case with serum B-1, which produced a nearly parallel leftward shift of the Scatchard curve (Fig. 6). With serum B-2 and B-3, however, the reduction of receptor number was not associated with a parallel shift in the Scatchard plot, implying an additional effect on receptor affinity to account for the total

FIGURE 6 Effect of antireceptor antibody on Scatchard plot for $^{125}$I-insulin binding. The data obtained from the experiment in Fig. 5 is plotted by the method of Scatchard as B/F hormone on the vertical axis versus the hormone bound in nanograms per milliliter on the horizontal axis.
TABLE I
Effect of Serum Pretreatment on Subsequent Binding of 125I-Insulin to IM-9 Cells

<table>
<thead>
<tr>
<th>Serum</th>
<th>Dilution</th>
<th>B/F at low (H)</th>
<th>R&lt;sub&gt;b&lt;/sub&gt;</th>
<th>K&lt;sub&gt;r&lt;/sub&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>% of control</td>
<td></td>
<td></td>
</tr>
<tr>
<td>B-1</td>
<td>1:4</td>
<td>38</td>
<td>50</td>
<td>90</td>
</tr>
<tr>
<td>B-2</td>
<td>1:600</td>
<td>25</td>
<td>60</td>
<td>39</td>
</tr>
<tr>
<td>B-2</td>
<td>1:60</td>
<td>4</td>
<td>19</td>
<td>11</td>
</tr>
<tr>
<td>B-3</td>
<td>1:80</td>
<td>23</td>
<td>55</td>
<td>32</td>
</tr>
</tbody>
</table>

The binding of 125I-insulin to IM-9 lymphocytes after preincubation with sera (data from Figs. 5–7) is expressed as percent of control binding, for (a) B/F at hormone (H) concentration, (b) receptor concentration (R<sub>b</sub>), and (c) average affinity at low receptor occupancy (K<sub>r</sub>.

reduction in steady-state binding observed at low hormone concentration.

To help clarify this parameter, we have used the average affinity profile (13), in which the average affinity of the system is plotted as a function of receptor occupancy (Fig. 7). With this graphic method it is apparent that the average affinity of the insulin receptor is reduced, to variable degrees by different sera, particularly at low degrees of receptor occupancy. The limiting high affinity obtained at low occupancy, K<sub>r</sub>, ranges from 11% of control with high concentrations of serum B-2 to 90% of control for serum B-1 (Table I). With increasing saturation by insulin, the K of the antibody-treated cells approaches that of controls, and the two are very similar at K<sub>r</sub> the limiting low affinity. Thus, the overall reduction in steady-state binding caused by these antibodies is the result of variable reductions of both receptor number and affinity. The effect of serum B-1 is primarily on receptor number, and the effect of serum B-2 and B-3 is primarily on receptor affinity, with a lesser effect on receptor number.

Effect of serum on association and dissociation of 125I-insulin. The association rates of 125I-insulin to cells pretreated with each sera were reduced when compared to control, and these effects were related to the concentrations of serum employed (Fig. 8). With each serum, the reduced association rate could result from reduction of receptor concentration, as well as from an alteration in association rate constant. When the data for association of 125I-insulin to cells treated with serum B-2 was fitted to a second order rate equation, a linear plot was obtained over the first 10 min of association (Fig. 9). The calculated rate constants (k) were seen to be reduced by serum treatment; with the highest serum concentration, a fivefold reduction of k was produced. Thus, reduction of association rate constant for insulin binding would appear to contribute to the reduced affinity of hormone binding to cells pretreated with serum B-2.

To assess the possibility that binding of antibody to the receptor could induce the phenomenon of negative cooperativity, and thereby account in part for the reduced affinity of antibody-treated cells for insulin, we examined the effect of purified antibody on the dissociation of prebound 125I-insulin (Table II). Addition to the dilution medium of an amount of antibody (from serum B-2) sufficient to cause an 80% reduction of tracer insulin binding had no effect on the dissociation rate of 125I-insulin bound to control cells when compared to the dissociation rate observed by dilution alone. This contrasts markedly with the ability of unlabeled insulin in the dilution medium to accelerate the dissociation of bound hor-

![Figure 7](image-url) Effect of antireceptor antibody on average affinity profile of 125I-insulin binding. The data from the experiment in Fig. 5 is plotted as (B/F)/R<sub>b</sub> - B, i.e., the average affinity (K) vs. B/R<sub>b</sub>, i.e., the percentage of total receptors that are occupied (Y).

Effect of Antireceptor Antibodies on the Insulin Receptor 789
mone under identical conditions. In this experiment, the accelerated dissociation of bound insulin by unlabeled hormone is indicative of the negatively cooperative site-site interactions that are a consequence

\textbf{TABLE II}

\textbf{Effect of Insulin and Antibody to the Insulin Receptor on Dissociation of $^{125}\text{I}$-Insulin from IM-9 Lymphocytes}

<table>
<thead>
<tr>
<th>Dilution medium</th>
<th>30 min</th>
<th>60 min</th>
<th>90 min</th>
</tr>
</thead>
<tbody>
<tr>
<td>Buffer</td>
<td>63</td>
<td>55</td>
<td>47</td>
</tr>
<tr>
<td>Buffer + antibody to the insulin receptor</td>
<td>65</td>
<td>60</td>
<td>51</td>
</tr>
<tr>
<td>Buffer + insulin (0.167 $\mu$M)</td>
<td>27</td>
<td>21</td>
<td>17</td>
</tr>
</tbody>
</table>

30 x $10^6$ IM-9 lymphocytes in 1 ml of assay buffer were incubated with 400 pg of $^{125}$I-insulin at 15°C for 90 min. Cells were sedimented and then resuspended in 1.0 ml of fresh buffer at 15°C. Duplicate 40-µl samples were placed into tubes containing (a) 4.0 ml of assay buffer at 15°C, (b) 4.0 ml of buffer at 15°C plus 0.167 $\mu$M unlabeled insulin, and (c) 4.0 ml of buffer at 15°C plus 25 $\mu$g/ml of purified IgG from serum B-2. At intervals, duplicate sets of tubes were sedimented, the supernate was removed, and the radioactivity in the cell pellet was counted. The radioactivity on the cells expressed as a percent of the radioactivity present at T = 0, is listed as a function of the time elapsed after dilution. The IgG was prepared by diethylaminoethyl (DEAE) cellulose fractionation of a resuspended 33% ammonium sulfate precipitate of serum (9). After 30 min of preincubation at 15°C with $2 \times 10^6$ IM-9 lymphocytes in a parallel experiment, this concentration of IgG caused an 80% inhibition of $^{125}$I-insulin binding (data not shown).
of insulin binding to its receptor (12). The effect of serum pretreatment on dissociation of insulin subsequently bound to the cell was also assessed. Cells were first treated with serum or buffer, and then allowed to bind labeled hormone, after which dissociation of tracer was measured by dilution of cells in a large excess of buffer as above. In addition, the effect of unlabeled insulin on dissociation of tracer by dilution was determined (12). Pretreatment of cells with sera B-1, B-3, and the lower concentration of B-2 (which produced comparable degrees of insulin binding inhibition) had no significant effect on spontaneous dissociation of ¹²⁵I-insulin at 15°C (Fig. 10). The higher concentration of serum B-2 produced a small (15–20%) but highly reproducible effect on spontaneous dissociation. On the other hand, preincubation with each serum caused unlabeled insulin to be less effective in accelerating the dissociation of bound ¹²⁵I-insulin from these cells. This effect was most pronounced with serum B-3 and with the higher concentration of B-2. Treatment with serum B-2 caused a rightward shift in the dose-response curve for insulin-induced acceleration of insulin dissociation, whereas treatment with sera B-1 and B-3 caused less enhancement of dissociation at each concentration of insulin (Fig. 11).

**DISCUSSION**

Peptide hormones and neurotransmitters initiate their actions through binding to specific receptors on the cell membrane (15). Defects at the level of the receptor would be expected to influence hormone action, and such defects might be expected to arise from a wide variety of possible mechanisms, both intrinsic and extrinsic to the cells in question. An interesting new mechanism by which receptor dysfunction may arise is the development of autoantibodies directed against specific membrane receptors (16). Such antireceptor antibodies are currently being

![Effect of antireceptor antibody on dissociation of ¹²⁵I-insulin from IM-9 lymphocytes. IM-9 cells were pretreated with serum or buffer, washed, and then incubated with ¹²⁵I-insulin at 15°C, in the presence and absence of 10 μg/ml of unlabeled insulin, as described in the legend to Fig. 8. After 90 min of incubation, 1-ml samples were removed, the cells were sedimented at 4°C, and then resuspended in 1 ml of fresh buffer at 15°C. 40-μl samples were then transferred to a series of tubes that contained 4 ml of buffer in the presence and absence of unlabeled insulin (1.67 μM, 15°C). At intervals, duplicate tubes of each set were sedimented, the supernate was removed, and the radioactivity in the cell pellet was counted. The radioactivity on the cells expressed as a percent of the radioactivity present at T = 0 is plotted as a function of the time elapsed after dilution. Each point is the mean of duplicates; duplicates differed by <5%. In each case, nonspecific binding (i.e., that which bound in the presence of 10 μg/ml insulin in the original association) was subtracted to yield specific counts.](image-url)
proposed in the pathogenesis of three diseases—myasthenia gravis, Graves’ disease, and the syndrome of extreme insulin resistance with acanthosis nigricans, type B (1, 5, 6).

In the latter syndrome, we have previously characterized the circulating immunoglobulins that bind to and block the membrane receptors for insulin (2, 3). In this report, we analyze in depth the effect of these antibodies on $^{125}$I-insulin binding, so as to better understand the nature of their interaction with the insulin receptor.

With insulin receptors on a human lymphoblastoid cell line (IM-9) as a model, inhibition induced by undiluted serum is rapid, with the two highest titered sera causing nearly maximal inhibition after <5 min exposure to the cells (Fig. 1). In addition, the extent of inhibition is quite marked, with at least 95% of specific insulin binding being blocked after incubation with serum B-2. Maximal inhibition may not have been reached after 3 h, particularly for sera B-1 and B-3.

Studies with appropriately diluted serum samples permitted comparative studies of time-course and temperature dependence of the inhibitory effect (Fig. 2). They indicate similar rates of onset of inhibition, and a single disparity with regard to temperature dependence of the effect. That is, whereas sera B-2 and B-3 produced maximum inhibition of insulin binding when exposed to cells at 37°C, serum B-1 was maximally effective at 22°C. This strongly suggests that serum B-1 recognizes a binding determinant on the membrane different from those recognized by sera B-2 or B-3. It should also be noted that the temperature dependence of antibody effect for all three sera is clearly different from that for insulin binding to its receptor (7). At steady state, insulin binding is characteristically greater at 4°C than at 22°C and this in turn is greater than that at 37°C.

In contrast to the rate of onset of inhibition, the rate of return of binding when cells are washed and placed in fresh buffer is very slow (Fig. 3). This presumably reflects slow dissociation of bound antibody, and may be the consequence of bivalent binding of antibody to clustered insulin receptors. This slow dissociation rate, which differs markedly from that of insulin, permits completion of the insulin binding assay (15°C, 90 min) under conditions in which antibody effect remains constant. Exposure of cells to acid conditions known to elute cell-bound antibodies produced a major restoration of insulin binding, confirming the reversible nature of the antibody effect.

Analysis of steady-state insulin binding to cells pretreated with antireceptor antibodies suggests combined effects on both receptor affinity and total $R_o$. With serum B-1, nearly all of the binding inhibition may be explained by reduction of $R_o$, with little or no effect on receptor affinity for insulin. In contrast, after exposure to sera B-2 and B-3, both $R_o$ and affinity are reduced, but major reductions of receptor affinity predominate. It should be noted that reductions in $R_o$ and affinity in this analysis may be considered analogous to the effects produced by "non-competitive" and "competitive" inhibitors, respectively, in the terminology of enzymology. Although mechanistic explanations for the nature of these effects on $R_o$ and affinity are speculative, we might envisage a reduction of $R_o$ to be the result of an essentially irreversible occupation of the receptor in such a way as to completely prevent insulin binding. On the other hand, a reduction of receptor affinity might result from antibody binding in such a way as to sterically hinder, but not entirely prevent, the binding of insulin. Combinations of effects on $R_o$ and affinity might result from heterogeneous antibody populations or from binding to intermediate sites.

Direct study of insulin association and dissociation...
tion kinetics with cells pretreated with antireceptor antibodies permitted further analysis of the mechanism by which reduction of affinity for insulin was produced. In this case, as with the analysis of steady-state binding (vide supra), a combination of effects is apparent. Thus, after exposure to serum B-2, we observe slower insulin association rate on the basis of reduced association rate constant, as well as enhanced dissociation rate of insulin from antibody-treated cells under the same conditions. The effects of these antibodies on insulin receptor affinity appear to be complex, and indeed may vary among sera, and with different concentrations of the same sera. It should be stressed, however, that the major mechanism by which these antibodies appear to reduce receptor affinity for insulin is by reducing the association rate constant for insulin binding. This is clearly distinguished from the mechanism by which insulin reduces the affinity of its receptor (i.e., negative cooperativity), which is through an acceleration of the dissociation rate.

The ability of insulin to induce site-site interactions of the negatively cooperative type is a characteristic feature of insulin receptors (12). It is of interest that treatment of cells with antireceptor antibodies appears to reduce the capacity of insulin to induce this phenomenon. Evidence on this point derives from both steady-state and kinetic data. First, analysis of steady state data for $^{125}$I-insulin binding to control cells with the “average affinity profile” (vide supra) is consistent with a fall in average receptor affinity with increasing receptor occupancy. This finding reflects negatively cooperative site-site interactions between insulin receptors, as demonstrated by direct kinetic experiments (12). When cells are treated with antireceptor antibodies, average affinity for insulin is reduced at low levels of receptor occupancy, with little or no reduction in affinity observed at the highest degrees of receptor occupancy. Thus, the degree to which receptor affinity is reduced with progressive occupancy by insulin is less marked in antibody-treated than in control cells. Further, treatment with each serum reduced the extent of negative cooperativity as determined by the direct kinetic experiment of De Meyts et al. (12). The dissociation of $^{125}$I-insulin from cells pretreated with antireceptor antibody was accelerated to a lesser degree by unlabeled insulin than was the dissociation of $^{125}$I-insulin from untreated cells. This resistance to the induction of negative cooperativity by insulin was seen over a wide range of insulin concentrations.

Thus, both kinetic and steady-state data suggest that antireceptor antibody binding reduces the capacity for negative cooperativity induced by insulin, although the mechanism of this effect may be complex. Several speculations seem reasonable. First, because negative cooperativity induced by insulin is a function of insulin binding to its receptor, we would expect inhibition of insulin binding caused by antibody to inhibit the ability of a given amount of insulin to induce negative cooperativity. According to this model, any insulin that did bind would induce cooperativity to the usual extent. Our current inability to analyze the dissociation data in a precise quantitative manner makes it difficult to compare the extent of binding inhibition with the reduction of cooperativity, and thereby determine whether binding inhibition is the sole mechanism for reduced cooperativity. However, binding of antireceptor antibodies might additionally impair the capacity for negative cooperativity by inducing slight alterations in the conformation of the receptor or its subunits (11). It is important to note that the addition of antibody to the diluting media in a concentration sufficient to reduce tracer insulin binding by 80% did not induce an acceleration in the dissociation rate of insulin bound to control cells, i.e., unlike insulin, the binding of antibody to the membrane did not cause cooperative interactions of the negative type between insulin receptors.

Thus, detailed analysis reveals that the inhibition of insulin binding caused by antireceptor antibodies may involve a variety of mechanisms. These include competitive occupancy of receptor sites, alteration of insulin association and dissociation kinetics, and interference with site-site interactions between receptors. Further use of these antibodies as probes of the insulin receptor may exploit one or more of these interesting effects. In addition, these antibodies may serve as a model for other studies of antibody effects on the interaction of ligands with important cell membrane receptors.

ACKNOWLEDGMENT
The authors wish to acknowledge Mrs. J. Smith and Mrs. C. Shinn for their excellent secretarial assistance.

REFERENCES